Compare Okta, Inc. (OKTA) vs Pfizer Inc (PFE) Price & Performance

Okta (OKTA) trades at $167.60, down 1.76% on the day, but remains up 94% year-to-date driven by strong earnings beats and AI-driven demand for cybersecurity. The stock exhibits a bullish technical trend, with moving averages signaling strength and key support at $166. Fundamentally, revenue grew to $2.61 billion in 2025 with a net income margin turning positive at 1.07%, while valuation ratios like P/E of 100.96 reflect high growth expectations. Recent news highlights AI security offerings boosting investor confidence.

Outlook is positive with a consensus price target of $181.61, indicating 8% upside, supported by 75% analyst buy ratings. Opportunities include expanding AI identity governance and enterprise adoption, but risks involve intense competition from CrowdStrike and Microsoft, high valuation multiples, and integration challenges. Net cash flow turned positive in 2025, though debt-to-asset ratio improved to 9.09%.

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.